Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2025-12-27 @ 6:15 PM
Study NCT ID:
NCT04068168
Status:
COMPLETED
Last Update Posted:
2025-11-17
First Post:
2019-08-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-30
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-27
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-07
First Submit QC Date:
None
Study First Post Date:
2019-08-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED